Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Generex Biotechnology has initiated enrollment of patients for a new Phase I clinical trial employing a immunotherapeutic cancer vaccine being developed at Antigen Express, its wholly-owned subsidiary.
Subscribe to our email newsletter
The new trial will employ two immunotherapeutic vaccines designed to work in concert to activate the immune system to recognize and kill tumor cells in breast and ovarian cancer patients.
The new trial will use the Antigen Express AE37 vaccine combined with another peptide vaccine to establish both safety and immunological response. Currently the AE37 vaccine is the subject of a Phase II clinical trial in patients with breast cancer and a Phase I trial in prostate cancer patients. Both vaccines are derived from the tumor-related HER-2/neu protein.
The trial is being conducted as part of collaboration between Antigen Express, George Peoples at the Brooke Army Medical Center and the Mary Crowley Cancer Center, which is funding the trial.